biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ
IO Biotech
IO Biotech is a biotech organization headquartered in copenhagen, DK. It trades on NYSE under ticker IOBTQ. Primary therapeutic focus areas include Melanoma, Previously untreated, unresectable, or metastatic melanoma, ad
Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK HQ
2015 Founded
50 Employees
Public company Type
IOBTQ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
- Founded
- 2015
- Employees
- 50
- Programs
- 16
- Drugs
- 8
- Patents
- 21
PD-L1 peptide
Phase 2 · mab · Smoldering Multiple Myeloma
PD-L1 peptide for Smoldering Multiple Myeloma is a Phase 2 program (mab) at IO Biotech with 1 ClinicalTrials.gov record(s).
Internal code MY18H2
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- IO Biotech
- Phase
- Phase 2
- Modality
- mab
- Indication
- Smoldering Multiple Myeloma
- Status
- terminated
- Trials
- 1